Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Get the iPhone MyHealth app »
Get the Android MyHealth app »
Association of time to second-line (2L) immune-checkpoint inhibitors (ICI) and outcomes with ICIs in patients (pts) with advanced urothelial carcinoma (aUC). Makrakis, D., Talukder, R., Dawsey, S., Carril, L., Stewart, T. F., Morales-Barrera, R., Park, J. J., Fulgenzi, C., Murgic, J., Vather-Wu, N., de Kouchkovsky, I., Devitt, M., Di Lorenzo, G., Gupta, K., Tripathi, N., Zakopoulou, R., Tripathi, A., Lu, E., Grivas, P., Khaki, A. LIPPINCOTT WILLIAMS & WILKINS. 2022
View details for DOI 10.1200/JCO.2022.40.6_suppl.505
View details for Web of Science ID 000771008900512